SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy

E. Pegoraro, E. P. Hoffman, L. Piva, B. F. Gavassini, S. Cagnin, M. Ermani, L. Bello, G. Soraru, B. Pacchioni, M. D. Bonifati, G. Lanfranchi, C. Angelini, A. Kesari, I. Lee, H. Gordish-Dressman, J. M. Devaney, Craig M McDonald

Research output: Contribution to journalArticle

135 Scopus citations

Abstract

Objective: Duchenne muscular dystrophy (DMD) is the most common single-gene lethal disorder. Substantial patient-patient variability in disease onset and progression and response to glucocorticoids is seen, suggesting genetic or environmental modifiers. Methods: Two DMD cohorts were used as test and validation groups to define genetic modifiers: a Padova longitudinal cohort (n = 106) and the Cooperative International Neuromuscular Research Group (CINRG) cross-sectional natural history cohort (n = 156). Single nucleotide polymorphisms to be genotyped were selected from mRNA profiling in patients with severe vs mild DMD, and genome-wide association studies in metabolism and polymorphisms influencing muscle phenotypes in normal volunteers were studied. Results: Effects on both disease progression and response to glucocorticoids were observed with polymorphism rs28357094 in the gene promoter of SPP1 (osteopontin). The G allele (dominant model; 35% of subjects) was associated with more rapid progression (Padova cohort log rank p = 0.003), and 12%-19% less grip strength (CINRG cohort p = 0.0003). Conclusions: Osteopontin genotype is a genetic modifier of disease severity in Duchenne dystrophy. Inclusion of genotype data as a covariate or in inclusion criteria in DMD clinical trials would reduce intersubject variance, and increase sensitivity of the trials, particularly in older subjects.

Original languageEnglish (US)
Pages (from-to)219-226
Number of pages8
JournalNeurology
Volume76
Issue number3
DOIs
StatePublished - Jan 18 2011

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy'. Together they form a unique fingerprint.

  • Cite this

    Pegoraro, E., Hoffman, E. P., Piva, L., Gavassini, B. F., Cagnin, S., Ermani, M., Bello, L., Soraru, G., Pacchioni, B., Bonifati, M. D., Lanfranchi, G., Angelini, C., Kesari, A., Lee, I., Gordish-Dressman, H., Devaney, J. M., & McDonald, C. M. (2011). SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology, 76(3), 219-226. https://doi.org/10.1212/WNL.0b013e318207afeb